Senate Finance Committee Turns Attention To Pfizer COX-2 Documents
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate Finance Committee is starting to review Pfizer documents on COX-2 inhibitors submitted in response to a December request
You may also be interested in...
Sen. Grassley's Proposed Drug Safety Office Would Have Labeling Authority
Finance Committee chairman is considering the feasibility of giving an independent drug safety office authority to suspend direct-to-consumer ads and marketing. The senator expects to offer legislation that would create the drug safety office soon, although the timeline may change based upon other legislators' actions.
Sen. Grassley's Proposed Drug Safety Office Would Have Labeling Authority
Finance Committee chairman is considering the feasibility of giving an independent drug safety office authority to suspend direct-to-consumer ads and marketing. The senator expects to offer legislation that would create the drug safety office soon, although the timeline may change based upon other legislators' actions.
Sen. Grassley Asks FDA, Pfizer To Detail Bextra Labeling Changes
The Senate Finance Committee request suggests there could be less flexibility in future label negotiations because of possible congressional scrutiny. Grassley also asks for briefings on Meridia, Crestor, Accutane and Serevent from FDA.